Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

49.02 -0.72 (-1.45%)
Official Closing Price Updated: 4:10 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,818,601
Open 49.89
Bid (Size) 49.04 (1)
Ask (Size) 49.07 (4)
Prev. Close 49.74
Today's Range 48.95 - 50.04
52wk Range 39.35 - 59.46
Shares Outstanding 2,222,113,553
Dividend Yield 4.65%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics. 
Via Investor's Business Daily
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
Via Investor's Business Daily

Performance

YTD
-7.09%
-7.09%
1 Month
-0.57%
-0.57%
3 Month
+19.44%
+19.44%
6 Month
-5.51%
-5.51%
1 Year
-16.39%
-16.39%

More News

Read More
Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
Via Benzinga
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
What Analysts Are Saying About Bristol-Myers Squibb Stock
Via Benzinga
Current Report: Bristol-Meyers Squibb (BMY)
Via Talk Markets
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
Via The Motley Fool
Merck Scores Two Key Victories With Keytruda In Women's Cancers
Via Investor's Business Daily
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
From Bristol Myers Squibb
Via Business Wire
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?'
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Via Benzinga
Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
From Bristol Myers Squibb
Via Business Wire
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
Via The Motley Fool
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
Via Benzinga
Exposures Product Safety
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
From Bristol Myers Squibb
Via Business Wire
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
Via The Motley Fool
2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now
Via The Motley Fool
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.